#fiercepharma

[meadowslark]

Worst deal ever? Bayer’s market cap now close to the total cost it paid for Monsanto

You don’t see me shedding any tears.

But there is even more Monsanto news:  Monsanto used former top DOJ official involved in Epstein case to quash felony charges .  Folks, things like this don’t just happen. Other than perhaps national security matters federal prosecutors - not DOJ administrators - determine who to prosecute and for what. (My thanks to Carey Gillam of US Right to Know and author of Whitewash for the “heads up” on this piece.  

[lucadezzani]

Best Websites for Pharmaceutical and Healthcare Updates

Best Websites for Pharmaceutical and Healthcare Updates

The rapidly changing environment of pharmaceutical and biotechnology industries and the need to keep pace with the constantly evolving business have driven large- and small-scale pharma companies, professionals, and consumers to continuously seek answers to certain questions involving latest drug development and company performance updates. Through the advancement in technology, most of these…

View On WordPress

[lucadezzani]

Top 10 Pharma Blogs 2016

Top 10 Pharma Blogs 2016

Pharmaceutical industry is renowned for innovation. New drugs are continuously being discovered and marketed around the world. Furthermore, new mergers and acquisitions are happening in the pharmaceutical industry on a regular basis, and new studies are being conducted quite regularly by the pharma companies. Hence, if you want to keep yourself updated with the latest developments in this…

View On WordPress

[pharmmsh]

2016/11/14 visitors

本日は真面目な話

いやはや忙しいね「Opdivo」。USAでキイトルーダとの頚頭部癌比較試験で非劣勢とでれば、EUでは消化器系癌のフェーズⅢで有効とのこと。まだまだ伸びそうだな。

国内O社さんはウハウハかなと思いきや、例の薬価カット問題が残っているため、そうでもないだろう。この辺の懸念事項と新規のParsabiv(etelcalcetide)との兼ね合いで決まるのかもしれないな(笑)。筆者的には、目下、Parsabivの薬価がいくらになるか気になっているところだ。尚、EUでのParsabiv承認情報は以下(英語が得意な方ね)

Amgen news release

European Commission Approves Parsabiv™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis

First Treatment Advance for Secondary Hyperparathyroidism in More Than a Decade and First Intravenous Calcimimetic to Help Healthcare Providers Lower Key Lab Values

THOUSAND OAKS, Calif., Nov. 11, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. Parsabiv is the first calcimimetic agent that can be administered intravenously by a healthcare provider three times a week at the end of a hemodialysis session...

続きはリンクで

[healthycity]

Sanofi's GLP-1 combo LixiLan bests both its ingredients in late-stage studies - FiercePharma

FiercePharma

Sanofi's GLP-1 combo LixiLan bests both its ingredients in late-stage studies Health – Google NewsSanofi’s GLP-1 combo LixiLan bests both its ingredients in late-stage studies – FiercePharma

Sanofi’s GLP-1 combo LixiLan bests both its ingredients in late-stage studies – FiercePharma was originally published on Health And Fitness Today

[healthycity]

Pharma-backed initiative delivers low-cost hep C drugs - FiercePharma

FiercePharma

Pharma-backed initiative delivers low-cost hep C drugs FiercePharma<... Health – Google NewsPharma-backed initiative delivers low-cost hep C drugs – FiercePharma

Pharma-backed initiative delivers low-cost hep C drugs – FiercePharma was originally published on Health And Fitness Today

[healthycity]

Pharma-backed initiative delivers low-cost hep C drugs - FiercePharma

FiercePharma

Pharma-backed initiative delivers low-cost hep C drugs FiercePharma<... Health – Google NewsPharma-backed initiative delivers low-cost hep C drugs – FiercePharma

Pharma-backed initiative delivers low-cost hep C drugs – FiercePharma was originally published on Health And Fitness Today

[medical-device-news]

Mylan Gets OK to Acquire Injectables Business

Mylan Inc. has cleared another hurdle in its planned acquisition of an Indian pharmaceutical company.

The Southpointe-based Mylan (Nasdaq: MYL) said it received approval from the Foreign Investment Promotion Board of India for its plan to acquire the…

View Post